Evaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Disease

Basit Öğe Kaydı
dc.contributor.authorEsenboga, Kerim
dc.contributor.authorKurtul, Alparslan
dc.contributor.authorNazman, Huseyin
dc.contributor.authorTekin, Cemre Gul
dc.contributor.authorOzyuncu, Nil
dc.contributor.authorTan, Turkan Seda
dc.contributor.authorTutar, Eralp
dc.date.accessioned2024-09-18T20:55:39Z
dc.date.available2024-09-18T20:55:39Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractNonalcoholic fatty liver disease (NAFLD) is the most common liver pathology in the developed world. Nonalcoholic fatty liver disease is associated with a higher risk of cardiovascular disease. We investigated the impact of ranolazine on liver tests in patients with NAFLD and coronary artery disease (CAD). Patients who had established CAD and NAFLD (as assessed by raised serum transaminase activity, sonographic criteria, and the absence of any other obvious liver disease) were allocated to on ranolazine (n = 40) or not on ranolazine (n = 35) groups. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in all patients at baseline and at the end of the study. After 6 months of ranolazine treatment, both ALT and AST activities were significantly lower in patients in the on ranolazine group compared with not on ranolazine patients (change from baseline: ALT, -11.0 +/- 1.7 IU/L, P < .001; AST, -5.2 +/- 1.9 IU/L, P =.009). In conclusion, the present study showed that treatment with ranolazine for 6 months led to a significant reduction in the activities of both serum aminotransferases in patients with stable CAD and NAFLD.en_US
dc.identifier.doi10.1177/00033197211005590
dc.identifier.endpage78en_US
dc.identifier.issn0003-3197
dc.identifier.issn1940-1574
dc.identifier.issue1en_US
dc.identifier.pmid33823622en_US
dc.identifier.scopus2-s2.0-85104068111en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage73en_US
dc.identifier.urihttps://doi.org/10.1177/00033197211005590
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11976
dc.identifier.volume73en_US
dc.identifier.wosWOS:000640815400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofAngiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectranolazineen_US
dc.subjectnonalcoholic fatty liver diseaseen_US
dc.subjectliver testsen_US
dc.subjectcoronary artery diseaseen_US
dc.subjectalanine aminotransferaseen_US
dc.subjectaspartate aminotransferaseen_US
dc.titleEvaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Diseaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
176.91 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu